BC Partners takes majority stake in Aenova Group
Context
BC Partners have signed a definitive agreement to acquire a majority stake in the Aenova Group from the European private equity firm Bridgepoint. This secondary LBO marks the end of Bridgepoint’s ownership period, which began in 2005, during which Aenova was transformed into one of Europe’s leading CDMOs. The current management team, led by CEO Heiner Hoppmann and CFO Frank Elsen, will remain at the helm to lead the next phase of the company's development. The strategic rationale for the acquisition is focused on leveraging Aenova’s superb market positioning to drive both organic and inorganic growth. BC Partners intends to utilize the group as a platform for further acquisitions to broaden its service range and enhance its competitive standing in international markets. For Aenova, the partnership with BC Partners provides the necessary capital to expand its "customer-centric" strategy and invest in innovative manufacturing technologies.
Aenova Group, which reported an EBITDA margin of [members only] in 2012, is valued in this transaction at an EV/EBITDA multiple of 5x–12x.
-> Deep-dive in Healthcare & Pharma market trends
Target
The Aenova Group is a leading global contract development and manufacturing organization (CDMO) serving the pharmaceutical and healthcare industries. Headquartered in Starnberg, Germany, the company operates as a comprehensive "one-stop shop" for the development, production, and packaging of a vast array of drug products. Its technical capabilities span all common dosage forms (including solid, semi-solid, liquid, sterile, and non-sterile applications) across both human and animal health. The group is particularly noted for its expertise in handling diverse active ingredient classes, ranging from standard pharmaceuticals to specialized food supplements, with high-containment capabilities (OEB 1 to 5). Its business model focuses on providing end-to-end supply chain services to global pharma companies, supported by a network of 14 specialized manufacturing sites across Europe and the USA. By combining operational excellence in conventional manufacturing with advanced technology platforms, Aenova addresses the complex regulatory and technical requirements of the modern pharmaceutical market, positioning itself as one of the ten largest CDMOs worldwide.
Ent. Value
€300–700M
Equity Value
[members only]
Multiples
EV / Revenue
1x–3x
EV / EBITDA
5x–12x
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Aenova Group
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 04/2024 | KÜHNE HOLDING | AENOVA GROUP | GERMANY | CDMO |
Other operations with BC Partners
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2018 | BC PARTNERS | FORNO D’ASOLO | ITALY | Bakery / Pastry |
| 10/2017 | BC PARTNERS | CERAMTEC | GERMANY | Glass & Ceramics |
| 05/2017 | BC PARTNERS | DENTALPRO | ITALY | Dental Centers |
| 07/2016 | BC PARTNERS / PSP INVESTMENTS | KETER | ISRAEL | Home & DIY |
| 11/2015 | BC PARTNERS | CIGIERRE | ITALY | Restaurants / Chains |
| 07/2015 | BC PARTNERS | CÔTE RESTAURANTS | UNITED KINGDOM | Restaurants / Chains |
| 06/2015 | BC PARTNERS | PHARMATHEN | GREECE | CDMO |
| 12/2014 | BC PARTNERS / CDPQ - CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | PETSMART | UNITED STATES | Pet Care |
| 06/2013 | BC PARTNERS | ANTELLIQ | FRANCE | Animal Health |
| 09/2005 | BC PARTNERS | FITNESS FIRST | UNITED KINGDOM | Hospitality |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2013 | ARDIAN | LABORATOIRES ANIOS | FRANCE | Medical Consumables |
| 07/2013 | CHARTERHOUSE | DOC GENERICI | ITALY | Generics / Labs |
| 06/2013 | EURAZEO | PÉTERS SURGICAL | FRANCE | Medical Consumables |
| 06/2013 | BC PARTNERS | ANTELLIQ | FRANCE | Animal Health |
| 01/2013 | ELITECH GROUP | VITAL DIAGNOSTICS | UNITED STATES | Diagnostic Equipment |
| 05/2011 | AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIA | LAGARRIGUE | FRANCE | Implants & Prosthetics |
| 09/2010 | SPARRING CAPITAL | IMV TECHNOLOGIES | FRANCE | R&D Biotech |
| 09/2009 | THE CARLYLE GROUP | MARLE GROUP | FRANCE | Implants & Prosthetics |
| 04/2007 | ASTORG | ETHYPHARM | FRANCE | Pharma & Biotech |
| 01/2006 | EDMOND DE ROTHSCHILD CAPITAL PARTNERS | ACTEON | FRANCE | Medical Devices |
REFERENCES
Valuation range: EV €300–700M
Revenue range: €250–500M
EBITDA range: €50–100M
EV/Revenue range: 1x - 3x
EV/EBITDA range: 5x - 12x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Aenova Group by BC Partners are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
FAQ
What transaction does this page cover?
How was the acquisition of Aenova Group by BC Partners valued, and what multiples were paid?
What were Aenova Group’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?